速递|美国国会议员呼吁FDA:打击司美格鲁肽等GLP-1仿制减重药泛滥!

GLP1减重宝典
26 Jul

整理 | GLP1减重宝典内容团队一批跨党派的美国国会议员正在敦促联邦卫生监管机构加强对日益猖獗的仿制和非法减重药市场的监管,原因是这些产品带来的安全隐忧不断上升。上周五,超过80名国会议员联名致信美国食品药品监督管理局(FDA),呼吁其采取措施,阻止如Wegovy和Zepbound等GLP-1类药物的仿制品涌入市场。近年来,这些最初用于治疗糖尿病、现广泛用于减重的药物,已成为非法复制与销售的目标...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10